Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet
Stock Information for Atossa Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.